Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The impact of mannose-binding lectin polymorphisms on lung function in primary ciliary dyskinesia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lung clearance index for early detection of pulmonary complications after allo-HSCT in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Tidal breath eNO measurements in a cohort of unsedated hospitalized neonates-A method validation

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The impact of chest computed tomography and chest radiography on clinical management of cystic fibrosis lung disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk factors during pregnancy and birth-related complications in HIV-positive versus HIV-negative women in Denmark, 2002-2014

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: The present study was performed to explore dosing regimens of colistin in patients of cystic fibrosis (CF) with Pseudomonas aeruginosa chronic biofilm lung infection.

METHODS: Ten CF patients were involved. One dose colistimethate sodium (CMS) of 6 MIU (million international units) and 9 MIU were administered by intravenous infusion over 45 and 90 min. Venous blood was collected at different time points after the infusion of CMS. Pharmacokinetic parameters of colistin were calculated. Minimum inhibitory concentration for planktonic P. aeruginosa, minimum biofilm inhibitory concentration and minimum biofilm eradication concentration of P. aeruginosa were determined. Monte Carlo simulation was performed to determine the clinical probability of target attainment of different dosing regimens of colistin in CF patients.

RESULTS: For 90 min (6 MIU), 45 min (6 MIU), and 45 min (9 MIU) intravenous infusion of colistin, Cmax was 8.9 ± 1.8, 15 ± 5.5, and 31.7 ± 5.3 μg/mL, respectively; Tmax was 1.2 ± 0.4, 0.7 ± 0.2, and 0.8 ± 0.2 h, respectively; AUCtot were 31 ± 3.8, 34 ± 10, and 135 ± 31mg · h/L, respectively; t1/2 was 2.1 ± 0.4, 2 ± 0.3, and 3.3 ± 0.4 h, respectively. MBIC and MBEC of colistin on biofilms at 24 h period treatment were 16-128 μg/mL for non-mucoid and mucoid biofilms of P. aeruginosa. For 90 min (6 MIU), 45 min (6 MIU) and 45 min iv infusion (9 MIU) with one dose colistin, PTA was 49.8%, 53.8%, 99.4% for planktonic infection, and 11.3%, 14.6%, 65.3%, respectively for biofilm infection.

CONCLUSIONS: colistin treatment using 45 min iv infusion is better than 90 min iv infusion in this study. Colistin dosage of 9 MIU is better than 6 MIU on both planktonic and biofilm infections of P. aeruginosa in this study.

Original languageEnglish
JournalPediatric Pulmonology
Volume54
Issue number5
Pages (from-to)575-580
Number of pages6
ISSN8755-6863
DOIs
Publication statusPublished - May 2019

ID: 59045512